A D.C. federal judge on Friday worked against drug manufacturer United Therapeutics Corp.’s effort to stop the U.S. Food and Drug Administration’s (FDA) potential approval of a new competitor for its highly successful pulmonary hypertension treatment, Tyvaso. The judge determined that United Therapeutics was essentially trying to contest an agency action prior to that action being decided upon by the FDA.
United Therapeutics was seeking to block the approval of a new drug that emerged as a competitor to its pulmonary hypertension remedy, Tyvaso. However, the judge in the case deemed the company’s actions as premature, as it attempted to challenge an agency action that the FDA had not yet finalized.
For more detailed information, you can refer to the original article from Law360.